The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | NIFTY and NALIRICC: Nal-IRI and 5-FU/LV in pre-treated biliary tract cancer
Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Korea, explores the pooled analysis of the NIFTY and NALIRICC trials (NCT03464968, NCT03542508) evaluating nanoliposomal irinotecan (Nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) as a second-line therapy for biliary tract cancer (BTC) following gemcitabine-based progression. Patients receiving the investigational therapy had better overall survival, but differences in safety profiles across ethnicities highlight the need for personalized treatment approaches in this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
